Source comparison
IPAM Same as Ipamorelin: Side-by-Side Research Profile Comparison
Before running any peptide protocol, understanding dosing windows, stability requirements, and expected biological responses is critical. Primary Mechanism IRS-1 activation, GLUT4 translocation, insulin sensitivity enhancement GHS-R1a agonism, pulsatile GH sec
This comparison does not assign a generated winner or score.
- Before running any peptide protocol, understanding dosing windows, stability requirements, and expected biological responses is critical.
- Primary Mechanism
- IRS-1 activation, GLUT4 translocation, insulin sensitivity enhancement
- GHS-R1a agonism, pulsatile GH secretion
- IPAM targets glucose metabolism; Ipamorelin targets growth hormone axis. Functionally non-overlapping
- Typical Research Dose (rodent models)
- 50–150 mcg/kg subcutaneous
- 200–300 mcg per administration
- IPAM dosed by weight; Ipamorelin dosed by absolute amount
- Half-Life
- 4–6 hours
- 2 hours
- IPAM allows once or twice daily dosing; Ipamorelin requires 2–3× daily for sustained effect
- Receptor Selectivity
- High selectivity for insulin pathway components
- High selectivity for GH release without cortisol/prolactin elevation
- Both demonstrate clean receptor profiles. Minimal off-target effects
- Storage Stability (lyophilised)
- −20°C, stable 24+ months
- Identical storage. Both degrade rapidly above 8°C once reconstituted
- Common Research Applications
- Insulin resistance models, glucose metabolism studies, AMPK pathway research
- Growth hormone deficiency models, body composition studies, aging research
- IPAM suits metabolic syndrome research; Ipamorelin suits anabolic/catabolic balance studies
- This comparison underscores why IPAM and Ipamorelin are not interchangeable. Selecting the wrong peptide for a given research question produces irrelevant data.